News & Updates

The Molecular Adsorbent Recirculating System (MARS), a nonbiological artificial liver device, leads to better clinical and biological outcomes among patients receiving the intervention, according to a recent study. However, adverse events and safety concerns related to the device are common.

While treatment with low-dose interleukin (IL)-2 leads to the expansion of circulating regulatory T cells (Treg), it does not appear to induce allograft tolerance among liver transplant patients, reports a new study.

Use of 20% albumin in patients with cirrhosis and sepsis-induced hypotension results in faster improvement in haemodynamics and lactate clearance than plasmalyte, but 28-day survival is similar, according to a study.

Treatment with semaglutide with firsocostat and/or cilofexor is well tolerated in patients with mild-to-moderate fibrosis due to nonalcoholic steatohepatitis (NASH), a study has shown.

Recipients of liver transplantation fare well with the use of statins, which a recent study showing that the drugs confer survival advantage.

The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.